Ikarian Capital, LLC Adc Therapeutics Sa Transaction History
Ikarian Capital, LLC
- $573 Million
- Q3 2024
A detailed history of Ikarian Capital, LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Ikarian Capital, LLC holds 300,000 shares of ADCT stock, worth $608,999. This represents 0.59% of its overall portfolio holdings.
Number of Shares
300,000Holding current value
$608,999% of portfolio
0.59%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ADCT
# of Institutions
80Shares Held
55.1MCall Options Held
82.7KPut Options Held
31.5K-
Redmile Group, LLC San Francisco, CA15.7MShares$31.8 Million3.23% of portfolio
-
Prosight Management, LP Dallas, TX9.64MShares$19.6 Million8.15% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.53MShares$9.2 Million0.34% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$7.22 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.04MShares$6.17 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $158M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...